



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

1614
JAN 22 2004
TECH CENTER 1600/2900

RECEIVED

IN RE APPLICATION OF:

Easterling

SERIAL NO. 10/083,625

FILED: 02/26/02

TITLE: VULVODYNIA

§
§
§
§
§
§
§

EXAMINER: KWON, BRIAN

GROUP ART UNIT: 1614

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action dated 09/10/03 in the above-referenced application, and below is requested an extension under 37 C.F.R. 1.136(a) (with deposit account fee charge authorization) to render this response timely. Please consider the following:

REMARKS AND ARGUMENTS

This is in response to the Office Action dated 09/10/03, and, pursuant to 37 C.F.R. 1.136(a), applicant requests a one-month extension of time to respond to such office action, extending the deadline from 12/10/03 to 01/10/04. The fee for such extension may be charged to the Deposit Account of the undersigned, Account No. 50-0894.

In response to Examiner's objections to Claims 4 - 7 under 35 U.S.C. § 103, it is respectfully submitted that Claims 4 - 7 are not obvious in view of the cited art. As the Examiner points out, the present invention teaches exact dosing requirements: specifically, "administering said dosage from



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

1614
JAN 22 2004
TECH CENTER 1600/2900

RECEIVED

IN RE APPLICATION OF:
Easterling

SERIAL NO. 10/083,625

FILED: 02/26/02

TITLE: VULVODYNIA

§
§
§
§
§
§
§

EXAMINER: KWON, BRIAN

GROUP ART UNIT: 1614

COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action dated 09/10/03 in the above-referenced application, and below is requested an extension under 37 C.F.R. 1.136(a) (with deposit account fee charge authorization) to render this response timely. Please consider the following:

REMARKS AND ARGUMENTS

This is in response to the Office Action dated 09/10/03, and, pursuant to 37 C.F.R. 1.136(a), applicant requests a one-month extension of time to respond to such office action, extending the deadline from 12/10/03 to 01/10/04. The fee for such extension may be charged to the Deposit Account of the undersigned, Account No. 50-0894.

In response to Examiner's objections to Claims 4 - 7 under 35 U.S.C. § 103, it is respectfully submitted that Claims 4 - 7 are not obvious in view of the cited art. As the Examiner points out, the present invention teaches exact dosing requirements: specifically, "administering said dosage from